

Introduction

At the inception of this project, I set out to study pharmaceutical industry practices to determine if they were ethical especially in terms of their profitability. This proved to be a much more complicated question than originally thought and was an impractical task to take on in a 13 week class. However I was able to gain a better understanding for why there is an idea that the pharmaceutical industry is unethical and why consumers have a belief that industry puts profits ahead of the patient. As the semester progressed I tended to look at how consumers viewed the pharmaceutical industry and how these views were shaped by different influences. Taking a step back and reviewing the installments in totality, showed many of my writings discussed an issue in which the consumer and industry had different views and how this affected their relationship. Their relationship is currently unstable as feelings of unease and distrust have developed among consumers in regards to the pharmaceutical industry. The negative opinion has formed in part because of highly publicized healthcare scandals that exposed the corruption within the industry. The United States healthcare industry is the world's biggest industry, with hundreds of billions of dollars spent on prescription drugs a year, however it has come to light that some profits were garnered via dishonest means (The Bureau, 2010). Recent scandals include "pharmafraud" which involves off-label marketing and covering up of side effects, physician kickbacks, and inaccurate marketing information (The Bureau, 2010). These scandals have helped to further a divide between industry and consumers as their perspective and opinions continue to diverge.

In order to bridge the gap between the two groups, their relationship has to be renewed with a focus on trust. As a consumer of pharmaceuticals and also a member of the industry through my work as a patient safety specialist I have a unique perspective which has allowed me to evaluate both sides of the argument. Therefore my project evolved into looking into the different approaches the consumer and industry take on these issues as a way to understand their individual perspectives and work towards narrowing the gap that exists between the two groups. My audience would be both employees of the Pharmaceutical Industry and consumers of pharmaceuticals. Understandably it is a broad audience, however in the context of this report; it needs to include both groups as they both need to change their outlooks. At the completion, I will have proposed some suggestions to be used by both consumers and the industry as a means to improve their relationship so both parties can benefit equally.

Orphan Disease Act: Influence Industry Research

Prior to the passing of the Orphan Disease Act in 1983, diseases that affected small populations of people were generally neglected. These diseases were so named "orphan" because they had been largely ignored by the healthcare industry and affected only a small number of individuals (health orphans)[Aronson, J. Rare diseases and orphan drugs]. The pharmaceutical industry did not pursue research or development to treat these diseases in part because it wasn't lucrative. To bring a drug to market requires considerable costs both in research efforts and money. The exact cost of drug development has been argued recently with industry purporting a figure of over a billion dollars while analysts claim it is overinflated as a way for the industry justify the high price of drugs (Herper, M. 2012). Despite the exact figure, there is undoubtedly a high cost for drug development. Therefore if profits weren't expected by the end of the process, companies wouldn't be eager to take it on. The Orphan

Drug Act was passed in 1983 and provided tax credits, extended patent protection, and simplification of marketing authorization procedures. These incentives essentially guaranteed pharmaceutical companies would make a profit if they pursued the development of orphan drugs. The guaranteed profit helped entice the industry to focus on the development of orphan drugs. By focusing research efforts on orphan diseases, did the industry genuinely intend to improve society, or were they thinking ahead of the opportunity to profit? Although understanding the true motive is difficult the perceived motive was profit and this contributed to the distrust by the consumers.

Consumers and patient advocacy groups tirelessly worked for the passing of the Orphan Disease Act because they recognized the lack of research and support for patients with Orphan Diseases. They correctly believed the Orphan Disease Act would spur industry to research and develop drugs for these diseases. They also correctly assumed the industry was at least partly motivated by profit. By increasing the opportunity to profit, the government in turn influenced the scientist's research. Instead of focusing on many disease areas, they were driven to concentrate their efforts on orphan diseases. The regulations inherently prevented competition, which in turn raised the prices of many of these drugs. The allowance of corporations to have a monopoly on orphan drugs resulted in high costs to the patients. For some drugs, such as Cerezyme, the average cost per year was \$250,000 and this treatment was required for a lifetime resulting in considerable costs to the consumer. The goal of the Orphan Disease Act may not have been to assist corporations in making substantial profit but ended up being one outcome.

With profit comes certain responsibly and ethical practices to uphold. Social responsibility is the company's obligation to improve society. The theory of social contract asserts there is a "contract" in place between the corporation and society. The corporations agree to act in such a way to be socially responsible while society "allows" them to be profitable (Makandi, P. 2010). Corporations may benefit society through such things as environmental initiatives or philanthropic efforts. Innate to the pharmaceutical industry is the ability to improve society through the development of life saving medication. The new attention on orphan diseases improved corporation's social responsibility because they now benefited more groups of people. However benefiting society isn't the only outcome of the social contract. Corporations recognized how important social consciousness was to consumers and used their efforts to enrich society as a marketing tool. Advertising their philanthropic efforts improved their reputation and in turn increased their ability to profit. Consumers can't help but consider how the social contract has become a business strategy as industry purports their "goodness" as a way to gain more profits.

The influence society has on the healthcare industry is far reaching but not always visible to the consumer. On a superficial level, it seemed the Orphan Disease Act was enacted to benefit individuals with orphan diseases. The intention may have been pure but as time went on and there become more advantages to the industry, the consumers began to feel as though they "fell victim" to the industry. Consumers were the ones who advocated for the passing of the Orphan Disease Act but in the end felt taken advantage of as the industry garnered profits. However do consumers need to feel taken advantage of? Can both parties benefit in different ways, consumers with life saving drugs and industry with profit? Why does it have to be one or the other? Why is profiting seen negatively by the consumer? Unfortunately further examination is required to answer these questions and thus they won't be answered in this paper but understanding each others' perspectives would be helpful in bettering the relationship between consumer and industry. Recognizing the advantages to each group and respecting the other's right to benefit would prove helpful as well.

Metaphors: Be More Careful

Metaphors are often used to make the complex more easily understood by the audience. Medicine is a complex subject but also affects everyone so it is important that analogies and metaphors are used as a way to make the concepts relatable. However metaphors also can create a bias and further the divide between industry and consumers and therefore must be used with caution.

One of the most widely used metaphors is the idea of medicine or pharmaceutical industries, “playing God.” There is the idea that industry is assuming God’s role by letting men live or die. It becomes an ethical debate whether or not man should have the ability to allow someone to die for example through assisted suicide or the ability to provide life through in vitro fertilization or human genetic engineering. The metaphor of “playing God” in this instance has negative connotations for health care industry. The industry is being viewed as over extending their authority. This popular metaphor is damaging to the industry’s reputation and perpetuates the negative feelings towards the industry by the consumer.

“Medicine is war” is a metaphor that relegates the patient to a lower position where the enemy is the disease and the doctors take on the disease using technologies which are seen as weapons. The patients are seen as “clinical material” and not as a major player in this “war.” In clinical trials subjects or patients are organized into cohorts within the phases of study. The word cohort, in Roman times, meant a set of identical and expendable soldiers used to win the battle (Hodgkin, P., 1985). To compare patients to an expendable participant rather than a major player demotes the importance of the patient in this war. Often the disease is viewed as an object rather than a process. Viewing disease as an “it” implies that it is something you can get rid of. A cure is seen as a physical removal of the disease and the patient is seen as a vessel for the disease. The patient is merely a container for the disease and thus is again seen as less important (Hodgkin, P., 1985). These metaphors put consumers in a negative light as they are passive players in their own disease. When diagnosed with any disease, the last thing a consumer wants is to feel is helpless. However when metaphors place patients as the central character it can also be misguided. The metaphor of “disease is an enemy” puts the disease in the patient’s control and they become responsible for “battling” the disease and ultimately being “victorious.” In this metaphor, patients who pass away are seen as weak because they aren’t able to “defeat” the disease. “Losing the battle” implies it was a something that could be won or lost, but diseases are not contests. This can be demoralizing to the patient whose health is deteriorating as they mistakenly believe it is their fault.

These examples show how metaphors can influence one’s views, and why then it is important to be careful when using them. Industry needs to make an effort to stop the media blitz of using the metaphor of the “disease being an enemy” because it puts too much pressure on the patient. They don’t have as much control over their health as the sentiments often imply. At the same time, consumers need to work on discontinuing the “playing God” metaphor because it furthers the idea of an arrogant industry that believes they are above everyone else. Metaphors can really permeate a culture and change people’s perspective which is why it is important to be responsible when using them and not further the divide between consumers and industry.

Supply Shortage: Media Coverage

In 2009 there was a shortage of the drug Fabrazyme which is manufactured by Genzyme Corporation. Fabrazyme treats Fabry disease, a lysosomal storage disorder which results in a buildup of

lipids within blood vessels and organs. Manifestations of the disease are dependent on where the buildup occurs but can cause renal failure, cardiac complications, and pain. When there was a shortage beginning in 2009 due to a virus in the bioreactors of Genzyme's manufacturing facility, patients publicly denounced the company—the same company they had previously lauded for saving their lives. Public denouement through the media can be especially damaging to corporations because news' reports are one of the biggest sources of information for society on current affairs. If these stories have an underlying tone, one that is not neutral, it can sway the reader's opinion. Journalists must therefore strive towards unbiased reporting. It is especially critical in reports covering the pharmaceutical industry because bias can perpetuate the distrust and further the divide between consumers and industry. The following articles written in response to the supply shortage have differing tones and exemplify how this can affect the reader's beliefs.

The patient accounts, those whose health was put in jeopardy, were highly critical of Genzyme and discuss their suffering publically. One patient interviewed by ABC news, refused to give his last name, in fear that Genzyme would single him out as a "trouble maker" and not provide him drug (James, S. 2011). Patients seemed to believe Genzyme was allocating drugs to certain groups of people and were not looking out for the entire patient population. Another patient echoed that sentiment as he stated, "...we are not confident they are doing everything they can for the Fabry community [community of patients with Fabry disease] (James, S. 2011)." Patients began to doubt Genzyme's commitment to the patient community. Patients, such as Olszewski who used to do speaking engagements for Genzyme and believed it was a wonder drug, now said, "I think they should be held on criminal charges for what they're doing to people...our tax dollars paid for the research and development of this drug, and they turn around and ship it to another country...it's nothing but greed (Silverman, E. 2011)". When companies fail to deliver what is promised, the consumer usually has a strong and immediate reaction against the company. A popular stereotype of the "money hungry" corporation against the "innocent" patient is often employed. The general public, many who are not involved in the shortage, will read these stories and continue to distrust the industry due to the harshly negative tone.

The drug shortage can also be viewed from a former employee's perspective, which is an interesting perspective because it is an insider account of the situation but is not the company's public statement. Mr. Boisvert, a lead maintenance technician, claimed he began looking into the conditions of the manufacturing facility in 2008 and noticed there were dead bugs, dust, rust, and mold growing within the rooms that were designated "clean rooms". The use of quotations within the story implies the room wasn't actually clean and triggers the reader to start to question the legitimacy of Genzyme's manufacturing practices. Mr. Boisvert went on to further explain that he took his concerns on the sanitation of the facility up his chain of command, eventually reaching the CEO but was told the problems wouldn't hurt anyone. Not happy with that response, he contacted the FDA directly with his issues and ultimately was fired by Genzyme (Lord, R., 2012). The story is structured with Mr. Boisvert as the main character, and the reader follows him as he makes his discoveries on Genzyme's flawed practices. The emphasis on Mr. Boisvert's efforts makes him appear as a hero for exposing Genzyme to the public. However we never see the other sides of the story, how the managers reacted to his claims, what new processes were implemented, what evidence they used to decide it wouldn't harm humans etc. Only Mr. Boisvert's opinion is important in this story and all other's opinions are dismissed. The use of a central character, one seen as a hero, is written with a bias against everyone who opposed Mr. Boisvert.

Genzyme's commitment to the patient did not waiver as much as these stories indicate. When the shortage was announced, Genzyme sent a letter to health care professionals which contrasts the patient accounts. These letters outlined an emergency access program that provided drug in safe, effective doses based on a dose maintenance study. All patients were considered and prioritized accordingly. If any patient deteriorated, resuming full dose was to be considered by the health care professional. The structure of these letters are objective and without emotion. They acknowledge the problem at the beginning and further outline the necessary processes that would be undertaken. In the closing, Genzyme recognizes that it is a temporary problem and welcomes requests for further information (Genzyme, 2009). This article is meant to be informative and subsequently is stoic and direct which sharply contrasts the expressive language used in the other stories. However, consumers can mistake the lack of emotion in the article for lack of concern.

Although it is understood that bias is inherent in writing, if a journalist minimized their bias and wrote with a neutral tone, it may improve the relationship between consumers and industry rather feeding into the distrust. Consumers rely heavily on the media for their news, and with that comes a certain amount of trust between the media and consumers. Therefore when the media publishes stories about the industry, consumers will believe the story and follow the tone of the report. If the media published more positive stories about the industry there would be a balance of information for the public to read which would help to improve the relationship between consumer and industry.

Reye's Syndrome: Social Actions without Established Causation

Part of the divide between industry and consumers can be attributed to the belief that scientists don't have a complete understanding of the disease before they promote or reject treatments. Consumers want to be able to trust the "experts" with providing them safe and efficient therapies. However, sometimes without a complete understanding of the cause, social action may be initiated in response to a scientist's *favored* causality rather than the true cause. Although the distrust is often directed at industry for not putting patient safety first, it is often the government who dictates regulations and initiatives that the industry is required to follow. Reye syndrome, an orphan disease, exemplifies this practice as social actions were put in place in reaction to the perceived association between aspirin and the syndrome, without an established causation.

Reye syndrome usually develops when a person is recovering from a viral illness and involves accumulation of fat in the liver and other organs. There is severe pressure on the brain and death is common within a few days unless it is diagnosed and treated early (reyessyndrome.org). Epidemiologic studies showed an association between aspirin use and Reye Syndrome (Weiner, D., 2012). As mentioned, Reye syndrome often develops following a viral infection and it was believed that the use of aspirin during the infection lead to the syndrome. More than 80% of individuals diagnosed with Reye Syndrome had taken aspirin within three weeks of their diagnosis, however less than 0.1% of children who took aspirin developed the condition (Weiner, D. 2012). Although a causal relationship wasn't established, government health authorities, nevertheless, sprang into action based on scientist's favored association between aspirin and Reye syndrome. Beginning after 1980, governing bodies including the Centers for Disease Control and Prevention, U.S Surgeon General, American Academy of Pediatrics, and the FDA all provided counsel. It was recommend that aspirin, or compounds containing salicylic acid, were not given to individuals under the age of 19 during illness induced by fever and companies were required to add warning labels to their drugs (Aspirin and Reye's Syndrome, 2012).

However these actions didn't satiate the consumer because they accused industry of not acting quickly enough and believed corporations pressured the government to delay the public warnings (Tanner, L., 1987). People criticized the pharmaceutical industry for thinking about their own interests ahead of patient safety. Consumers seemed to believe the industry delayed adding warnings to their product because they didn't want sales to decrease. The industry argued that any perceived delay in warning labels was due to the lack of causation. Few cases linked aspirin use to Reye's syndrome and further research and discussions were required. Industry did not want to purport what was not scientifically sound without further research (Tanner, L. 1987). Despite concerns with the association, industry did comply with government imposed regulations and included a warning on their label. Even recently scientists have claimed that Reye's syndrome may have been a viral mutation or was caused by metabolic disorders that were not been recognized (Orlowski, J. et al., 2002). Studies show the syndrome disappeared from countries where aspirin was not used in children and in countries where aspirin continued to be prescribed despite warnings (Orlowski, J. et al., 2002). There have been no animal models which show causation or demonstrations that salicylates are in the blood or urine of Reye's syndrome patients (Orlowski, J. et al., 2002). These results support the actions of the industry in being cautious with promoting the association.

A relationship with mutual respect and trust will never develop between industry and consumers if there is an idea that companies would jeopardize patient safety for profits. It is important that industry makes it known that they value and protect patient safety. As an employee within the safety department of pharmaceuticals, it is easy for me to see how safety is supported and appreciated by the industry; however consumers don't have the ability to see this firsthand. Once there is doubt that industry is not protecting consumer, there is an immediate divide. Therefore industry must make an effort to show their commitment to patients and consumers must be willing to forgo their preconceived beliefs.

Crohn's Disease: Unknown Cause but Many Treatments

It is critical to determine the cause of diseases because understanding the cause not only leads to treatment but also provides insight on prevention. However sometimes there isn't just one cause, often there are multiple causes and a multitude of solutions and preventions. The complexity of the causes can be confusing and can lead to misunderstandings on how to approach a treatment or prevention. Treatment for diseases is of significance because finding and utilizing the right treatment can be tremendously beneficial to affected patients while a lack of appropriate treatment can be debilitating and in severe cases fatal. However good patient care, also means understanding why a disease happens and how it could be prevented (Rose, G. 1985). Understanding risk factors and recognizing individuals who are susceptible to certain diseases would be beneficial to society by reducing incidence rates.

One of the more visible orphan diseases, Crohn's disease, exemplifies why it is so critical to look at all the factors that lead to a disease when developing treatment. Crohn's disease is an autoimmune disorder where the body's immune system attacks and destroys the healthy tissue and leads to inflammation of the gastrointestinal tract. Symptoms include abdominal pain, fatigue, weight loss, loss of appetite (Board, A.D.A.M. Editorial. *Crohn's Disease*). There are many theories as to what causes the disease but none have been proven. Research shows that the disease can be caused by a combination of immune system problems, genetics, and environmental factors. It is believed that genetics plays a role because scientists identified a gene associated with the disease where if the gene is mutated the body

will react to microbes differently than a normal reaction and overtime can develop into Crohn's disease (WebMD). Environmental factors also have an influence on the development of the disease. Some factors may trigger the disease but not necessarily cause Crohn's disease while other factors may directly damage the lining of the intestines (WebMD). Since there are a multitude of causes, it is difficult for physicians to treat the disease. Often patients change their diet, avoiding foods that cause flare ups and take medications to reduce inflammation (WebMD). There is also a new therapy that uses stem cells to replace cells of damaged tissues which has its basis in the genetic/cellular causes of the disease (ScienceDaily). Without a cause, there can be no prevention. Despite the lack of preventive measures, certain actions can be taken to minimize the severity of symptoms which include regular exercise, healthy diet, abstinence from smoking, and use of non-NSAID for pain.

Crohn's disease represents only one orphan disease in which the cause is unknown but many factors leading to its development are known. Treatment options can be unique to the cause and if some causes are not recognized and explored, some valuable therapies could be neglected. If research was only focused on one cause of the disease, the patient might not receive adequate treatment. Researching the cause not only helps in treating Crohn's disease but also may lead to the development of preventive measures. If the disease can be successfully prevented, treatments won't need to be pursued. However, there may be an idea among consumers that industry isn't working towards preventing the disease because it means they will lose sales. If the disease can effectively be prevented, treatments won't be necessary and companies who manufacture these therapies will lose profits. This idea, although especially jaded, exemplifies the sometimes strong distrust by the consumer. We see consumers again re- questioning industry's' motives. Whether or not they are right in their distrust, companies still need to reinforce their commitment to patients. This may be done through better communication to the patients regarding their research efforts both in prevention and treatment as a way to emphasize their dedication to patient's health.

Green Pharmaceuticals: Helping the environment or a company's profit margin?

The potential eco-toxicity of pharmaceutical drugs is becoming a popular issue as society's focus on protecting the environment grows. Drug residues can end up in the environment through human excretion as well as through improper disposal of excess medication. The growing awareness of the negative impacts on the environment has forced the pharmaceutical industry to create "green pharmaceuticals." Calling these new drugs, "green" implies that the currently produced drugs are not "green." It can therefore be deduced that general perception does not believe pharmaceuticals are safe for the environment. However no significant research has been published to date that indicates pharmaceutical waste is harmful to human health. Studies have detected low levels in the environment which are unlikely to affect humans although there is a recognized potential for impacting aquatic life (GlaxoSmithKline, 2011). Despite the lack of strong evidence, consumers might be hesitant to consume drugs that are not "green."

In response to consumer's desire for environmentally safe pharmaceuticals, industry has begun to develop drugs that are "green." Green pharmaceuticals are generated with a reduced impact on the environment both during development and in consumption. There is a limited use or no use of hazardous substances in the process (EEA Workshop, 2010). However creating these drugs is a challenge to the industry as many drugs are stable and effective *because* of their resistance to degradation. Additionally, bringing drugs to market is a long expensive process. To add another criterion

for market approval is not something companies would be eager to take on unless it was beneficial to them in terms of profit. Therefore there must be incentives for creating “greener pharmaceuticals” much like the incentives to create drugs for orphan diseases. During a European Environment Agency (EEA) workshop held in 2010, a patent system that would encourage companies to measure the environmental impact of the drug along with its safety and efficacy was suggested. The patent would be extended for drugs that are “benign by design.” The profits garnered while under the extended patent would offset the costs to research the environmental impact (EEA Workshop, 2010).

The focus on creating drugs safe for the environment may be viewed as a business strategy rather than a true concern for the environment. Products become more marketable and subsequently profitable when it fits society’s needs, which in this case is an environmentally friendly drug. This business strategy taken together with the proposed incentives for creating green pharmaceuticals would directly increase a company’s profits. The initial response by corporations was to accommodate patient desires; however it could become a way for them to increase their profit margin. Similar to the aforementioned Orphan Disease Act, there is a benefit to both parties involved albeit in different ways. However consumers may feel taken advantage of, initially believing their concerns were supported by the industry but instead were used in business strategy. Again the question is raised, why does one party have to become the “bad guy” when both groups are benefiting? The group who takes on this “bad guy” role is dependent on perspective; therefore a possible solution would be to minimize the bias and respect one another’s position.

Forums: Improving Patient Outlook

Gaucher disease is a lysosomal storage disease which means it affects the lysosomal activity of cells. The lysosomes are missing an essential enzyme that breaks down fatty substances; therefore lipids accumulate in cells and certain organs. Prior to the development of Cerezyme, patients with Gaucher disease were provided palliative care to treat their symptoms because there was no therapy focused on treating the disease itself. Cerezyme is a form of enzyme replacement therapy in which the missing enzyme, beta-glucocerebrosidase, is manufactured in the lab and infused into the patient. With this enzyme, the deficient activity of the enzyme is normalized and the lipids can be broken down and removed from the body rather than accumulated. If the patient is started on treatment early, they will experience very minimal symptoms and can live an active, normal lifestyle.

However, the medication is required for life and costs approximately \$250,000 a year. The drug is taken intravenously and depending on the patient can take 2-4 hours every two weeks to infuse. Taken the high costs and the long administration, patient compliance can be difficult. Patients may feel healthy and take it upon themselves to go on “drug holiday” or they may be tired of going to the infusion center every two weeks and decide to skip some infusions. The symptoms of the disease will come back and some of them are irreversible such as avascular necrosis or liver damage. To combat the angst associated with the disease, there are several patient support groups for the Gaucher community such as the National Gaucher Foundation and National Organization for Rare Disorders. These groups provide resources and advice for patients experiencing the disease and adjusting to the treatment regimen. Genzyme recognized the need for patient support and has a patient advocacy department within the company which provides live webinars, information on legislations as well as health insurance assistance. Due to the criticality of patient adhering to therapy, these resources can be incredibly beneficial.

Providing patient support through forums or support groups will certainly narrow the divide between industry and consumers. When corporations provide support, it humanizes the patients and makes them believe they are more than just a number to the corporations. It means the corporations genuinely care for them and their health. Further interactions between patients and industry will only continue to improve the relationship. Additionally, current research in Gaucher disease is focused on developing an oral therapy that provides the same results without requiring the biweekly infusions. The idea that research is directed at making consumer's lives easier furthers the notion that patients are a priority to corporations.

Looking Forward: Evolution and Extinction

The pharmaceutical industry, as we know it today, is a nascent industry and increasingly susceptible to change. These changes can be viewed in the frame of evolution. Evolution as taught in the classroom is the concept of descent with modification where inherited characteristics change over generations. One mechanism of evolution is natural selection. Natural selection is not directed at a defined goal, it is an outcome of differences among organisms as they respond to their current environment. Companies who are able to adapt to the changing environment will succeed while those that cannot, will eventually go bankrupt or be bought out by a larger company. This is comparable to the concept of survival of the fittest where those organisms with favorable traits will flourish while those without will die off. As society and technology change, the environment in which the pharmaceutical industry operates will change and thus companies need to change in parallel to stay in business. These changes may, for example, be in demographics, regulations, globalization, or attitudes of the patients and investors. Companies compete for resources similar to how Darwin described organisms competing for resources in his "On Origin of Species." Unlike organisms that compete for food, space, and mates among other things, companies compete for investments, patients, and knowledge. As companies struggle to survive, they need to adapt their structure and capabilities.

Changing in response to the environment is not the only means by which a corporation can "evolve." For example, during scientific research mistakes can be made which end up being successful discoveries. When these mistakes happen in industry, it can completely change the direction of the company. For example if a company was focused on developing treatment for renal cell carcinoma but in the process, discover a mechanism to treat hypertension the company may redirect its resources to now focus on developing treatment for hypertension. This chance discovery can be compared to a random mutation in the DNA of an organism. Both happen by chance and both may lead to an "evolution" of sorts.

There are many ways a corporation can change and many reasons for the change. However, if corporations do not evolve as the market landscape changes, there may be extinction of some business strategies or in some cases extinction of the entire company through bankruptcy or acquisitions. The pharmaceutical industry, more so than many other industries, has a high rate of "extinction." It is difficult for companies to obtain the necessary resources of capital and knowledge and at the same time adapt to the changing environment. Those that don't go "extinct" have the ability to change by some means and by some degree. It is important that industry appreciates the criticality of evolving as a means to avoid extinction. The divide that currently exists between the pharmaceutical industry and consumers could lead to extinction of some companies because the healthcare market recently has put more emphasis on the patient and is becoming consumer driven. Therefore to follow the theory of evolution as it applies to the pharmaceutical industry, companies should consider changing their

business strategy in response to this changing landscape. The pharmaceutical industry should work towards fostering a better relationship with consumers as outlined in this report. Going forward concentrate solutions would prove more successful in bridging the gap between the groups but the most critical improvements are in fostering trust and opening the lines of communication-the key to any successful relationship.

References:

- Genzyme Corporation. Research and Development. *Direct Healthcare Professional Communication on the Supply of Cerezyme (imiglucerase) and Fabrazyme (agalsidase Beta) Temporary Treatment Recommendations*. N.p., n.d. Web. 3 Oct. 2012. <http://www.imb.ie/images/uploaded/documents/2009-06-24%20DHPC%20Cerezyme%20and%20Fabrazyme_UK.pdf>.
- JAMES, SUSAN DONALDSON. "Fabry Disease Patients Get Sicker as Drugs Go Overseas." *ABC News*. ABC News Network, 30 Aug. 2011. Web. 03 Oct. 2012. <<http://abcnews.go.com/Health/fabry-disease-patients-sicker-sue-drug-company-lifesaving/story?id=14403759>>.
- Silverman, Ed. "Genzyme Angers Patients Over Fabrazyme Supplies." *Pharmalot*, 04 Aug. 2011. Web. 03 Oct. 2012. <<http://www.pharmalot.com/2011/08/genzyme-patients-angry-over-fabrazyme-supplies/>>.
- Lord, Rich. "Patients Suffer as Drug Maker Rations Fabrazyme Medicine." *Pittsburgh Post-Gazette*. N.p., 30 Mar. 2012. Web. 28 Nov. 2012. <http://www.post-gazette.com/stories/local/region/patients-suffer-as-drug-maker-rations-fabrazyme-medicine-305547/>
- Aronson, J. K. "Rare Diseases and Orphan Drugs." *British Journal of Clinical Pharmacology* (2006): 243-45. NCBI. Web. 31 Oct. 2012. <British Journal of Clinical Pharmacology>.
- Makandi, Puriry. "Social Contract Theories in Business." *EHow*. Demand Media, 15 Nov. 2010. Web. 13 Nov. 2012. <http://www.ehow.com/list_7503426_social-contract-theories-business.html>.
- "New Therapy With Stem Cells To Treat Crohn's Disease." *ScienceDaily*. ScienceDaily, 21 Feb. 2009. Web. 07 Nov. 2012. <<http://www.sciencedaily.com/releases/2009/02/090219105326.htm>>.
- "What Causes Crohn's Disease? Genetics, Immune System Problems, and More." *WebMD*. WebMD, n.d. Web. 07 Nov. 2012. <<http://www.webmd.com/ibd-crohns-disease/crohns-disease/crohns-disease-causes>>.

Aspirin and Reye's Syndrome: National Reye's Syndrome Foundation." *Aspirin and Reye's Syndrome: National Reye's Syndrome Foundation*. N.p., n.d. Web. 24 Oct. 2012.

<<http://www.reyessyndrome.org/aspirin.html>>.

Orlowski, J. P., U. A. Hanhan, and M. R. Fiallos. "Result Filters." *National Center for Biotechnology Information*. U.S. National Library of Medicine, 2002. Web. 24 Oct. 2012.

<<http://www.ncbi.nlm.nih.gov/pubmed/11994026>>.

Tanner, Lindsay. "Doctor Hits Aspirin Makers on Reye Syndrome Warnings." *Doctor Hits Aspirin Makers on Reye Syndrome Warnings*. Associated Press, 11 Apr. 1987. Web. 25 Oct. 2012.

<<http://www.apnewsarchive.com/1987/Doctor-Hits-Aspirin-Makers-on-Reye-Syndrome-Warnings/id-339258d4af6c07b9109ce08bb7d56057>>.

Weiner, Debra L., MD. "Reye Syndrome." *Reye Syndrome*. Medscape Reference, 10 Aug. 2012. Web. 25 Oct. 2012. <<http://emedicine.medscape.com/article/803683-overview>>.

Hodgkin, Paul. "Medicine Is War: And Other Medical Metaphors." *British Medical Journal* 291 (1985): 1820-821. Web. 18 Oct. 2012. <<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1419170/pdf/bmjcred00479-0084.pdf>>.

Pharmaceuticals in the Environment. Rep. N.p.: European Environmental Agency, 2010

Rose, Geoffrey. "International Journal of Epidemiology." *Sick Individuals and Sick Populations*. International Journal of Epidemiology, n.d. Web. 28 Nov. 2012. <<http://ije.oxfordjournals.org/content/30/3/427.full>>.

Gsk. "Public Policy Issues." GlaxoSmithKline, Nov. 2011. Web.

<<http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK-on-pharmaceuticals-in-environment.pdf>>.

The Bureau. "Documentary Reveals the Unhealthy Profits of the Pharmaceutical Industry." *The Bureau of Investigative Journalism RSS*. N.p., 11 Aug. 2010. Web. 11 Dec. 2012.

Herper, Matthew. "The Truly Staggering Cost Of Inventing New Drugs." *Forbes*. Forbes Magazine, 10 Feb. 2012. Web. 11 Dec. 2012.

"Reye's Syndrome Information from the National Reye's Syndrome Foundation." *Reye's Syndrome Information from the National Reye's Syndrome Foundation*. National Reye's Syndrome Foundation, n.d. Web. 11 Dec. 2012.

Board, A.D.A.M. Editorial. *Crohn's Disease*. U.S. National Library of Medicine, 18 Nov. 0000. Web. 11 Dec. 2012.